{"id":"W4309093661","doi":"10.1158/1078-0432.ccr-22-2074","title":"A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer","year":2022,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Imperial Experimental Cancer Medicine Centre; National Institute for Health and Care Research; Sierra Oncology; Cancer Research UK","keywords":"Gemcitabine; Medicine; Neutropenia; Internal medicine; Cancer; Tolerability; Nausea; Lung cancer; Cervical cancer; Gastroenterology; Oncology; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Adverse effect; Chemotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009059039,0.001130949,0.001242401,0.0003848985,0.0003359879,0.0006688082,0.0004739713,0.0006032955,0.002724165],"category_scores_gemma":[0.0004788164,0.0003540075,0.000668551,0.0003993549,0.0006797927,0.0004363071,0.0002198808,0.00211017,0.000522762],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008499669,"about_ca_system_score_gemma":0.001705403,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008803197,"about_ca_topic_score_gemma":0.002454221,"domain_scores_codex":[0.9997333,0.0001238931,0.00001539584,0.00004747543,0.00002711885,0.00005275986],"domain_scores_gemma":[0.9996305,0.00005709862,0.00007294665,0.00002448013,0.00002408066,0.0001909095],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6575366,0.06429698,0.00916928,0.001049041,0.001133442,0.0003720344,0.0002205356,0.003580275,0.09607582,0.000387767,0.004268674,0.1619095],"study_design_scores_gemma":[0.4870971,0.4897683,0.01002516,0.0000390911,0.0004692965,0.0003004761,0.00004393881,0.002256131,0.007684603,0.0001551468,0.002134108,0.00002666442],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9962172,0.0009593293,0.0002922766,0.0001963213,0.00006433686,0.0009615908,0.0002910508,0.00005777925,0.0009600784],"genre_scores_gemma":[0.9950003,0.0008364925,0.001008033,0.0003115741,0.000101672,0.000760439,0.000910398,0.00001372135,0.001057291],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002724165,"threshold_uncertainty_score":0.009113252,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1206781321433797,"score_gpt":0.5118891438458054,"score_spread":0.3912110117024257,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}